In another study, anti-PD-1 immunotherapy combined with patient-derived prostate-specific microbe CP1 injection, there was notable improvement in survival rates and a reduction in tumor size in orthotopic models of MYC- and PTEN-mutant PCa syngeneic models 187. This evidence concerns the gene PDCD1 and neoplasm.